Cellectis: 2014 Financial Results

Regulatory News:

Cellectis SA (Alternext:ALCLS) publishes its consolidated financial statements for 2014, as approved by the Board of Directors at their meeting on March 3, 2015.

• Total revenues and other income amounted to €26.4 M. This is mainly due to the collaboration agreements signed with Servier and Pfizer.
• Net loss for the period is €-0.972 M, including a loss of €2.8 M for the Tools and Services segment which operations were sold or terminated in 2014.
• As of December 31, 2014, shareholders’ equity was €59.5 M, and cash and cash equivalents were €112.3 M.
• The accounts for the year ended December 31, 2014, have been audited. The audit reports are being prepared.
• As mentioned in the press release dated February 20, 2015, we draw your attention to the fact that some figures for the year ended December 31, 2013, are different from what has previously published. These corrections are explained in more details in a note which can be accessed following this link: http://www.cellectis.com/sites/default/files/corrections_comptes_20022015_0.pdf

About Cellectis

Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS).

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.